RARE PHOTOS: Regn | Rare Historical Photos

An $8 Billion Reason Why Regeneron Stock Is in Focus

Regeneron announces an expanded deal with Sanofi. Here’s what the disclosure really means for REGN shares.

Barchart · Oct 2

Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?

Regeneron Pharmaceuticals has outpaced the healthcare sector, and analysts remain moderately optimistic about the stock’s outlook.

Barchart · Sep 2

Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

Regeneron Pharmaceuticals has comfortably outperformed the S&P 500 over the past year, and Wall Street remains reasonably bullish on the company’s long-term growth prospects.

Barchart · Aug 26

Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.

Regeneron stock sinks as fianlimab Phase 3 trial fails to meet primary endpoint. But RBC continues to see significant upside in REGN shares from here.

Barchart · May 18

Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report

Regeneron Pharmaceuticals is expected to announce its fiscal first-quarter earnings this month, and analysts project a low single-digit earnings drop.

Barchart · Apr 14

Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Although Regeneron Pharmaceuticals has lagged the Nasdaq over the past year, analysts remain highly bullish about its prospects.

Barchart · Feb 28

Is Wall Street Bullish or Bearish on Regeneron Pharmaceuticals Stock?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and analysts remain highly upbeat about the stock’s growth potential.

Barchart · Feb 20

Regeneron Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know

Regeneron Pharmaceuticals will release its fourth-quarter earnings later this month, and analysts anticipate a double-digit profit dip.

Barchart · Jan 6

Is Regeneron Pharmaceuticals Stock Underperforming the S&P 500?

Regeneron Pharmaceuticals has underperformed the S&P 500 over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Barchart · Nov 28, 2025

Are Wall Street Analysts Bullish on Regeneron Pharmaceuticals Stock?

Regeneron Pharmaceuticals has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart · Nov 21, 2025